MaxCyte, Inc. MaxCyte Announces Collaboration to Advance CARMA (4115S)
December 21 2016 - 2:00AM
UK Regulatory
TIDMMXCT
RNS Number : 4115S
MaxCyte, Inc.
21 December 2016
MaxCyte Announces Collaboration to Further Advance CARMA
- Preclinical research to focus on developing therapies based on
MaxCyte's proprietary CARMA platform
- CARMA has potential for broad applicability against solid or liquid tumor indications
Gaithersburg, MD, December 21, 2016 - MaxCyte(R), Inc.
(AIM:MXCT) today announces a strategic collaboration with
Washington University in St. Louis, a leading institution in acute
myeloid leukemia (AML) research. MaxCyte and the university will
develop unique immunotherapy drug candidates, based on MaxCyte's
proprietary cell engineering platform technology, CARMA.
CARMA allows simple and rapid manufacture of advanced cancer
treatments that utilize a patient's own immune system and is
differentiated from traditional CAR therapy due to its use of mRNA
to engineer immune cells delivered back into a patient. By
utilizing transient expression via mRNA delivery, CARMA allows
control over severe adverse effects, opening the high potency of
CAR immunotherapies to a broader range of cancers than traditional
CAR approaches.
"We're excited to initiate this collaboration with Washington
University in St. Louis, one of the leading medical research
centers worldwide, to develop a new generation of CAR therapy for
blood cancers using MaxCyte's CARMA therapeutic platform," said
Doug Doerfler, President & CEO of MaxCyte, Inc. "This
collaboration is a natural extension of our efforts in this new
class of therapies, given our previously announced collaboration
with the Johns Hopkins Kimmel Cancer Center for pre-clinical
development of CAR therapy for solid cancers. Our CARMA platform
shows great promise for developing therapies for patients with both
solid and liquid tumor types. It provides rapid, cost-effective
manufacturing and delivery of cellular therapies to patients
without many of the toxicities associated with other CAR-based
approaches."
John DiPersio, M.D., Ph.D., Chief of the Division of Oncology at
Washington University School of Medicine and Deputy Director of the
Siteman Cancer Center, and members of his team will collaborate
with MaxCyte to conduct preclinical research with a focus on
developing a potential investigational CAR therapy targeting acute
myeloid leukemia and other related blood cancers. Financial terms
were not disclosed.
The preclinical studies that the two collaborators anticipate as
a result of this agreement will take advantage of the rapid,
low-cost therapeutic development and manufacturing process enabled
by the MaxCyte technology. As such, the financial commitment in the
program would not be significant at this stage.
About the CARMA Platform
Researchers are investigating the use of CARMA, the Company's
patented approach to CAR, to generate the next class of
immunotherapy for cancer, aiming to improve on patient outcomes for
those with either solid or liquid tumor types. CARMA-engineered
immune cells seek and destroy cancer cells with the potential to
deliver precise therapies for patients against a range of cancers,
without the cost and complexity of centralized manufacturing and
adverse effects seen in first-generation, viral-based CAR
therapies. MaxCyte believes that the promising preclinical results
obtained from the collaboration with The Johns Hopkins Kimmel
Cancer Center, along with further studies, will result in an
investigational new drug ("IND") filing with the US Food and Drug
Administration ("FDA") in 2017 for patients with ovarian cancer.
The Company continues to explore new targets and additional
collaborators to advance the CARMA platform.
About MaxCyte
MaxCyte is an established and revenue generating US-based
developer and supplier of cell engineering products and services to
biopharmaceutical firms engaged in cell therapy, drug discovery and
development, biomanufacturing, gene editing and immuno-oncology
markets, which independent market analyses estimate to be, in
aggregate, in excess of $35 billion in 2015. The Company's patented
flow electroporation technology enables its products to deliver
fast, reliable and scalable cell engineering to drive the research
and clinical development of a new generation of medicines.
MaxCyte's high performance platform allows transfection with any
molecule or multiple molecules and is compatible with nearly all
cell types, including hard-to-transfect human primary cells. It
also provides a high degree of consistency and minimal cell
disturbance, thereby facilitating rapid, large scale, clinical and
commercial grade cell engineering in a non-viral system and with
low toxicity concerns. The Company's cell engineering technology
platform is CE-marked and FDA-accredited, providing MaxCyte's
customers and partners with an established regulatory path.
Using the unique capabilities of its technology, MaxCyte is
developing CARMA, its proprietary platform in immuno-oncology, to
deliver a validated non-viral approach to CAR therapies across a
broad range of cancer indications, including solid tumors where
existing CAR-T approaches face significant challenges.
For more information visit http://www.maxcyte.com/
This announcement contains inside information for the purposes
of Article 7 of Regulation (EU) No 596/2014 (MAR).
###
MaxCyte +1 301 944 1660
Doug Doerfler, Chief Executive
Officer
Ron Holtz, Chief Financial
Officer
Nominated Adviser and Broker
Panmure Gordon
Freddy Crossley (Corporate
Finance)
Fabien Holler
Duncan Monteith
Tom Salvesen (Corporate Broking) +44 (0) 20 7886 2500
Financial PR Adviser +44 (0)203 709 5700
Consilium Strategic Communications maxcyte@consilium-comms.com
Mary-Jane Elliott
Chris Welsh
Lindsey Neville
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCURABRNUAUUAA
(END) Dow Jones Newswires
December 21, 2016 02:00 ET (07:00 GMT)
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Jul 2023 to Jul 2024